Balanced news tone
News Sentiment
XCUR sentiment intelligence
Exicure Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-4.0% over one week, -27.3% over four weeks, trend inactive, and below fair value.
XCUR stock trades on limited evidence as Exicure waits for filings
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Cash from operating activities of Exicure, Inc. – DUS:2H0
This article focuses on the "Cash from operating activities" for Exicure, Inc. (DUS:2H0), a company listed on the Dusseldorf Stock Exchange. The content appears to be a financial data point from a trading platform, indicating specific values and percentage changes over a period,
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 15:41
- Source
- TradingView
Exicure Inc (XCUR) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Exicure Inc (XCUR), noting its current financial score of 4.76 and ranking it 383 out of 389 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating efficiency is low. The report
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 15:09
- Source
- TradingKey
Total equity of Exicure, Inc. – DUS:2H0
This article provides financial information for Exicure, Inc. (DUS:2H0), specifically focusing on its total equity. The content is sourced from TradingView and includes data from ICE Data Services and FactSet, along with SEC filings from Quartr.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 11:10
- Source
- TradingView
Exicure, Inc. Balance Sheet – DUS:2H0
This article provides details on Exicure, Inc.'s balance sheet (DUS:2H0), highlighting its financial position as of Q1 2026. The company's total assets were 11.04 million EUR, a 12.68% decrease from Q4 2025, while total liabilities decreased by 0.83% to 9.22 million EUR in the sa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:10
- Source
- TradingView
Exicure Inc (XCUR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Exicure Inc's (XCUR) dividend and stock split history. It notes that the company has distributed no dividends over the past five years but details several merger-related stock splits, including one recently on August 26, 2024, at a 5-to-1 rati
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 05:10
- Source
- TradingKey
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 20:01
- Source
- GlobeNewswire
Exicure faces Nasdaq listing deadline as equity sits at $2.1M vs $2.5M
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 20:00
- Source
- GlobeNewswire
Exicure faces Nasdaq noncompliance over late 10-Q, then files report
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
Exicure Inc. (XCUR) Q2 2022 Earnings: Wider-than-Expected Loss, No Revenue, Shares Edge Higher - Margin Guidance
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 23 May 2026 07:00
- Source
- dars.gov.et
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Exicure, Inc. Reports Full Year 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Mar 2026 07:00
- Source
- The Globe and Mail
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 05 Mar 2026 08:00
- Source
- Stocktwits
Insider Sell Alert: Hitron Exicure Sells 734,747 Shares of Exicu
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 20 Jan 2026 08:00
- Source
- GuruFocus
Exicure Inc.: Is It a Bet Worth Taking?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Dec 2025 08:00
- Source
- timothysykes.com
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jan 2025 08:00
- Source
- BioSpace
Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Jan 2025 08:00
- Source
- Stock Titan
Biotech company Exicure's new path isn't in biotech
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2023 07:00
- Source
- Crain's Chicago Business